Purpose: We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin
(IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer …

4031 Background: Capecitabine is an oral fluoropyrimidine that has demonstrated similar
efficacy to 5-FU/LV in the 1st-line treatment of MCRC. Most patients now receive multi-agent …

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but mortality
associated with this disease has declined in recent decades due to improved screening …

Background Elderly and frail patients with cancer, although often treated with chemotherapy,
are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose …

Aim Colorectal cancer survivors are one of the most rapidly growing groups of patients living
with and beyond cancer. In a national multidisciplinary setting, we have examined the extent …

The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical
management, perioperative treatment, posttreatment surveillance, management of recurrent …

Colorectal cancer (CRC) is a major cause of death, particularly in the Western world, leading
to 400,000 deaths each year [1]. Of the patients, 30% have advanced disease at …

Background Studies evaluating new systemic agents tend to report severe toxicities only,
while the cumulative effect of multiple lower grade adverse events (AEs) may have an …

Over the past decade treatment for metastatic colorectal cancer (mCRC) has advanced
beyond single-agent fluoropyrimidine use to include various cytotoxic combination regimens …

Antitumour therapy in advanced colorectal cancer has limited efficacy. For decades,
fluorouracil has been the main anticancer drug for the treatment of colorectal cancer …